Skip to content

AIM Market Roundup: Celadon Pharma, Oracle Power, Zinnwald Lithium

AIM Market Roundup: Celadon Pharma, Oracle Power, Zinnwald Lithium

The see-saw of AIM continues with the all share backing down around four points today ahead of tonight’s hotly awaited tariff update from Trump. The Index closed at 684.29.

  • Celadon Pharmaceuticals +150%
  • Oracle Power +31%
  • Zinnwald Lithium +12%
  • Electric Guitar -79%
  • Brighton Pier -61%

Celadon Pharmaceuticals LON:CEL was the biggest gainer, up 150%. The share price had been squeezed in recent days after an update highlighted issues faced in terms of funding the company needed to survive. There’s no formal note out by the assumption would be for a move of this scale that the money has either been received – or there’s strong conviction the cash is on its way.


Oracle Power LON:ORCP was 31% higher. Again there’s no fresh news out – an update at the start of the week failed to generate much of a reaction but volumes have been notably elevated during the session.

Zinnwald Lithium LON:ZNWD was 12% higher. A regional government in Germany has reiterated its support for the company, emphasising its value in providing an independent supply of Lithium to the local market. This is useful support following the company’s failure to secure CRMA status in last week’s EU review.

Electric Guitar LON:ELEG was the biggest faller, off 79% after trade in the company’s stock returned to trading following a four month suspension. A significant amount of restructuring has taken place but investors have been left diluted. The market cap sits now at just £130k.

Brighton Pier LON:PIER also struggled, falling 60% after the company announced that it intended to delist, citing the usual points including cost and lack of liquidity. Subject to shareholder approvals, shares will be moved to a matched bargain facility.2

Share this article

Invest with these platforms

Interactive Brokers eToro Charles Stanley Hargreaves Lansdown IG
Interactive Brokers eToro Charles Stanley

Looking for great investing ideas? Get our free newsletter

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

WisdomTree
ARK
Pepperstone
eToro

FP Markets
aberdeen
CME Group
Schroders

Back To Top